1082058-99-8

Basic information

• Product Name: 4-[2-(2-methylphenyl)ethynyl]-benzenepropanoicacid
• Synonyms: 4-[2-(2-methylphenyl)ethynyl]-benzenepropanoicacid;TUG 424;CAY10587;3-(4-(o-Tolylethynyl)phenyl)propanoic acid;FODHWOBAQBTTFS-UHFFFAOYSA-N
• CAS NO: 1082058-99-8
• Molecular Formula: C₁₈H₁₆O₂
• Molecular Weight: 264
• Mol File: 1082058-99-8.mol

Chemical Properties

• Boiling Point: 448.1±38.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Storage Temp.: Store at +4°C
• Solubility: DMSO: >10mg/mL
• PKA: 4.62±0.10(Predicted)
• CAS DataBase Reference: 4-[2-(2-methylphenyl)ethynyl]-benzenepropanoicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(2-methylphenyl)ethynyl]-benzenepropanoicacid(1082058-99-8)
• EPA Substance Registry System: 4-[2-(2-methylphenyl)ethynyl]-benzenepropanoicacid(1082058-99-8)

Safety Data

• Hazard Codes: Xi,N
• Statements: 36-50/53
• Safety Statements: 26-60-61
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 1082058-99-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Efavirenz is used as an antiretroviral medication for the treatment of HIV/AIDS. It is employed to inhibit the reverse transcriptase enzyme, thereby preventing the replication of the virus and managing the infection. The use of efavirenz in combination with other antiretroviral drugs helps in effectively controlling the viral load and reducing the risk of developing drug resistance.
Used in HIV/AIDS Management:
Efavirenz is used as a key component in the management of HIV/AIDS. It plays a crucial role in improving the prognosis and quality of life for individuals living with the disease. By inhibiting the activity of the reverse transcriptase enzyme, efavirenz helps in reducing the viral load and preventing the progression of the disease.
Despite its effectiveness, efavirenz may cause some side effects, such as dizziness, vivid dreams, and mood changes, which can affect some patients. However, its benefits in the management of HIV/AIDS outweigh the potential side effects, making it an essential drug in the fight against the disease.

Upstream product

• 1082059-32-2 methyl 3-(4-(o-tolylethynyl)phenyl)propanoate 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES

There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type Il diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

A rapid and efficient Sonogashira protocol and improved synthesis of free fatty acid 1 (FFA1) receptor agonists

(Chemical Equation Presented) Aprotocol for rapid and efficient Pd/Cu-catalyzed coupling of aryl bromides and iodides to terminal alkynes has been developed with use of 2-(di-tert-butylphosphino)-N-phenylindole (cataCXium PIntB) as ligand inTMEDA and wate

Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a potential target for the treatment of type II diabetes

A series of 4-phenethynyldihydrocinnamic acid agonists of the free fatty acid receptor 1 (FFA1) has been discovered and explored. The preferred compound 20 (TUG-424, EC50 = 32 nM) significantly increased glucose-stimulated insulin secretion at 100 nM and may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity.